These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9817536)

  • 1. Multiple sclerosis: use of MRI in evaluating new therapies.
    Miller DH
    Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
    Ozawa K; Saida T
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
    Zivadinov R
    Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.
    Simon JH
    West J Med; 1996 Jun; 164(6):502-9. PubMed ID: 8764625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of MRI in patients with multiple sclerosis].
    Tourbah A
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1124-7. PubMed ID: 11787344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Goodin DS
    Ann Neurol; 2006 Apr; 59(4):597-605. PubMed ID: 16566022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroimaging in multiple sclerosis.
    Miller DH; McDonald WI
    Clin Neurosci; 1994; 2(3-4):215-24. PubMed ID: 7749891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI to monitor treatment efficacy in multiple sclerosis.
    Fazekas F; Soelberg-Sorensen P; Comi G; Filippi M
    J Neuroimaging; 2007 Apr; 17 Suppl 1():50S-55S. PubMed ID: 17425736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
    Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
    Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients.
    Rumbach L; Racadot E; Armspach JP; Namer IJ; Bonneville JF; Wijdenes J; Marescaux C; Herve P; Chambron J
    Mult Scler; 1996 Feb; 1(4):207-12. PubMed ID: 9345436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.